Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?
about
Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733Antibodies: At The Nexus of Antigens and Cancer VaccinesIdiotypic cascades in cancer patients treated with monoclonal antibody CO17-1AMonoclonal antibodies--therapeutic and diagnostic uses in malignancy.Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patientsAnti-idiotype immunization of cancer patients: modulation of the immune responseChimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.Possibilities for active immunotherapy of human cancer.Possible role of anti-idiotypic antibodies in the induction of tumor immunityHuman monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I.Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccinePatients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens.Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving antiidiotypic antibodies.Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.Epitope- and antigen-specific cancer vaccines.Phototherapy and photopharmacology.Monoclonal antibodies for cancer immunotherapy.Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigenIsolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants.Modulation of tumor immunity by therapeutic monoclonal antibodies.Potential applications of monoclonal antibodies in cancer diagnosis and therapy.Rational design and application of idiotope vaccines.Anti-idiotypic tumor vaccines.Modulation of cancer patients' immune responses by anti-idiotypic antibodies.Drug-targeting by monoclonal antibodies.Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?Tumor immunology: an overview.New human single chain anti-idiotypic antibody against benzo[a]pyrene.A novel human monoclonal antibody directed to a tumor-associated antigen.The Gordon Wilson lecture. Monoclonal antibodies in human cancer.Protection against a syngeneic mammary adenocarcinoma by administration of idiotypic and anti-idiotypic antibodies.A non-toxic enzyme-linked immunosorbent assay for aflatoxin B1 using anti-idiotypic antibodies as substitutes.A human monoclonal antibody recognizing a surface antigen on stomach cancer cells.
P2860
Q24629156-C2990E3E-D94D-4D7C-82A9-EA50C712EE89Q27001058-7F0EC252-C994-432D-A2DA-C7494B5CD57BQ33858524-B46D4750-BD2C-4CAF-8378-01E95D9B80B4Q34193200-00983BA3-0C28-4D20-ADFF-0238B791EC09Q34262315-95F6939F-9968-4C4C-BB29-390C67ACA6C9Q34366216-C5847F87-093C-439D-A234-05D7C3C91970Q34625006-766B7EC1-30E8-4E2A-9786-837965477D73Q35326752-82810A98-8FC8-4A84-B357-E1F9BDFCD7C9Q35580948-1773AC6C-DD54-4562-9BE6-4BB96569F2A5Q35600692-179A8B68-D2CA-4A94-9DD3-FF790BDC4BB7Q35750646-F09BEAD2-0BA4-4ED6-9FD2-35D1E6884D83Q35993724-52858FC3-CE58-4C91-8A42-966548FA1BCFQ36350167-08D194DF-9159-488A-835F-AA43BB7A0E8EQ36410563-D6C21B6B-6290-4AA2-9AF1-14B1CCA23C4DQ36930069-B3615D1B-2759-4385-88D6-9453690C460BQ36989020-610ED76C-C9FA-43FF-BBF5-2C68D3847E8AQ37181031-0E2B598C-62BC-444F-9A1D-550704268239Q37400018-023C5F64-B240-49E3-B74F-A513073F0CF6Q37486766-7324F27E-51AF-4BB9-86F6-995BAFB2B2D0Q37558378-2E8AB169-35C0-4958-82AC-EE2A868C5FF6Q37832438-21176F03-1DC8-41B9-B7B9-8E757A227508Q38157384-E1BA1C29-3A36-42E9-828E-24F8A4768D6CQ38204525-EA7B61BD-2E87-42C2-8CCC-20F8D501765CQ38246921-D2CDBF6A-0CD9-46AE-AACE-2272AF918360Q38246922-7C793356-CAF4-4E5A-886D-B6D87CCFCDA4Q39763669-DB91B7A9-D505-4FCD-A3BE-60BD8CC8A6ACQ40672537-89962CC6-CB2A-4C1F-B706-DF1C50CA21BEQ40844492-38A43FEC-4E5F-41B9-8D2C-368712B72C2EQ41539697-42AC0A56-05C2-413C-BC90-A6C4623A5947Q41543369-05F25968-8F1B-4CB3-8910-9F771A2E41F2Q41779247-379C9F76-523B-4A04-B31A-58892321284AQ44643940-80F7583D-D853-4404-9AA1-166A9A9D70F0Q51240502-6A9D3777-3879-4C08-8D5D-DB5FBCB1F09AQ55317230-82E9FAA4-27A7-440C-8982-909AF83865D7
P2860
Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Human anti-idiotype antibodies ...... se beneficial for the patient?
@ast
Human anti-idiotype antibodies ...... se beneficial for the patient?
@en
type
label
Human anti-idiotype antibodies ...... se beneficial for the patient?
@ast
Human anti-idiotype antibodies ...... se beneficial for the patient?
@en
prefLabel
Human anti-idiotype antibodies ...... se beneficial for the patient?
@ast
Human anti-idiotype antibodies ...... se beneficial for the patient?
@en
P2093
P2860
P356
P1476
Human anti-idiotype antibodies ...... se beneficial for the patient?
@en
P2093
P2860
P304
P356
10.1073/PNAS.81.1.216
P407
P577
1984-01-01T00:00:00Z